AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VOR
  4. [8-K] Vor Biopharma Inc. Reports Material Event

[8-K] Vor Biopharma Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock VOR logo
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

#3928 Ranked by Market Cap
N/A Ranked by Dividends

VOR Latest News

Aug 13, 2025
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Aug 4, 2025
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Jul 21, 2025
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Jul 18, 2025
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2025
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

VOR Latest SEC Filings

Aug 12, 2025
[10-Q] Vor Biopharma Inc. Quarterly Earnings Report
Aug 11, 2025
[144] Vor Biopharma Inc. SEC Filing
Aug 8, 2025
[DEF 14A] Vor Biopharma Inc. Definitive Proxy Statement
Aug 6, 2025
[SCHEDULE 13G/A] Vor Biopharma Inc. SEC Filing
Aug 4, 2025
[144] Vor Biopharma Inc. SEC Filing

VOR Stock Data

255.81M
70.68M
43.75%
46.53%
11.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE